Four Team Handoffs to Define for Autonomous and Remotely Operated Medical Devices

Medical-device employers developing robotic systems with autonomous or remote-teleoperation capabilities face a role-planning question: who owns each technical decision, safety control, and handoff as the device’s work shifts between software, remote operators, and on-site teams?

In November 2026, FDA’s Center for Devices and Radiological Health released a discussion paper on benefit-risk considerations for these systems. FDA says the paper is intended to invite early stakeholder feedback. It is not draft or final guidance, does not propose a policy change, and does not communicate FDA’s proposed or final regulatory expectations. FDA also states that, as of July 2026, no remotely teleoperated or fully autonomous robotic device systems had received U.S. marketing authorization. That dated statement is useful context, not a forecast of adoption or hiring. The comment deadline is January 5, 2027, and FDA has announced a public workshop for December 2–3.

For an employer, the paper is a prompt to map handoffs—not a template for a required organization chart. Its scope includes diagnostic, therapeutic, and rehabilitative robotic devices, with or without surgery, and discusses both systems that act with some autonomy and systems controlled remotely in real time. For a separate but related scope, see our guide to hiring for robotically assisted surgical devices under FDA’s September 2026 premarket-submissions draft guidance; this article focuses on the November discussion paper’s autonomous or remote-teleoperation handoffs.

Map the system’s four control handoffs

Start with the device, intended use, development stage, users, and operating setting. Then map where control or responsibility moves. For each handoff, write down four things before opening a search: the event that triggers the handoff, who has decision authority, what the next person or system must do, and what evidence shows the transition works as intended. This keeps a role brief tied to a specific responsibility instead of an expansive “robotics” title.

Use this as a planning worksheet, not a prescribed organization chart. The accountable owner depends on the device, intended use, operating environment, and the employer’s own design and quality processes.

These are employer questions prompted by topics FDA raises for discussion. They are not FDA-assigned job functions or claims that every program needs four separate positions.

FDA’s paper describes autonomy as a spectrum. Remote operation also varies: it can involve a specific task or a larger portion of a procedure. These are useful planning distinctions, but FDA presents them as discussion terms, not a final classification system. The company’s product and regulatory leaders should define the language used in each role brief.

1. System action to user oversight

Specify which actions are autonomous, what the user must approve or supervise, and what event returns control to a user. FDA’s paper discusses the possibility that a user may shift from performing an action to overseeing it as autonomy increases. For the requisition, identify whether the hire owns control logic, the interface that communicates system state, the human-factors evidence, or a defined partnership across those areas. In a structured interview, ask the candidate to explain a non-confidential example of how they established a human intervention point and verified that users could recognize and act on it.

2. Remote operator to on-site team

Identify what the remote operator controls and what the local team must prepare, observe, override, or handle if a procedure changes. FDA raises issues such as adverse-event management, reduced sensory awareness at a distance, and the availability of qualified local support. Define which role designs the remote workflow, which local responsibilities remain with the care team, and who coordinates an escalation. Ask candidates to describe how they made a remote-to-local interface clear, what assumptions they tested with users, and what they changed after testing.

3. Normal connection to degraded or lost connectivity

State which system behaviors are expected when a connection degrades, what evidence demonstrates them, and who coordinates the device, network, cybersecurity, and facility interfaces. FDA asks stakeholders about connectivity standards, engineering controls, facility capabilities, personnel qualifications, and evidence related to unexpected connectivity degradation or cybersecurity breaches. Ask a candidate to walk through a relevant failure scenario: what the system should communicate, what behavior is acceptable, how recovery is handled, and what test evidence supports the decision. Keep the exercise within the candidate’s claimed expertise; the employer must define its own acceptance criteria.

4. Development evidence to field feedback

Name the owners for risk controls, human-factors and usability work, verification and validation scenarios, and postmarket monitoring. FDA discusses a range of nonclinical and clinical methods and testing across scenarios, including worst-case conditions. It also identifies user oversight, training, and postmarket review as possible risk-mitigation areas. Ask how a candidate has connected a field issue, user observation, or test result to a documented risk review and a decision about further evaluation. Do not ask for confidential records or former-employer details. The specific ownership should follow the employer’s design, quality system, and regulatory strategy; FDA is not prescribing job titles in this discussion paper.

Turn the handoff map into a focused search

For each responsibility, separate the work the new hire must own on day one from work handled by quality, regulatory, clinical, systems, network, cybersecurity, facility, or external testing partners. Write down the first-year deliverables and the decision-maker who approves them. Then label each qualification as essential on day one or trainable after joining. That makes the posting clearer to qualified candidates and gives interviewers a shared basis for evaluation.

This process may point to a systems, software, controls, verification, cybersecurity, quality, regulatory, or human-factors search—or show that the work belongs across several existing roles. Evaluate the work a candidate actually owned and the evidence they can discuss, rather than expecting one person to cover every discipline.

Keep hiring plans tied to the actual program

FDA’s paper is an early discussion, not a requirement to create new positions or evidence of increased hiring demand. Employers should use their own product plans, design controls, risk process, and approved staffing decisions to determine whether and when a role is needed. Revisit the brief when intended use, system behavior, operating environment, or team responsibilities change.

For related hiring in medical-device production engineering and process transfer, see HealthStaffingGroup’s guide to scoping a medical-device manufacturing engineer role and its medical-device manufacturing and engineering recruiting practice. HealthStaffingGroup supports employers with permanent medical-device and MedTech recruiting. Request an employer consultation to discuss a defined hiring need.

Primary source

FDA: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities — Discussion Paper and Request for Feedback, November 2026.